1H-Pyrazolo[3,4-d]pyriMidin-4-aMine, 1-[trans-4-(4-Methyl-1-piperazinyl)cyclohexyl]-3-(4-phenoxyphenyl)-

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1H-Pyrazolo[3,4-d]pyriMidin-4-aMine, 1-[trans-4-(4-Methyl-1-piperazinyl)cyclohexyl]-3-(4-phenoxyphenyl)-
• 英文别名: 1-[4-(4-methylpiperazin-1-yl)cyclohexyl]-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-amine
• 化学式: C₂₈H₃₃N₇O
• 分子量: 483.6
• InChiKey: RLVCBYBGVBOVFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  85.3
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Pyrazolopyrimidines as therapeutic agents
  申请人：Abbott Laboratories

  公开号：US20020156081A1

  公开（公告）日：2002-10-24

  The present invention provides compounds of Formula I, 1 including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R 2 , and R 3 are defined as described herein.

  本发明提供了公式I的化合物，包括其药学上可接受的盐和/或前药，其中G、R2和R3的定义如本文所述。
• [EN] A PYRAZOLOPYRIMIDINE DERIVATIVE AS A HCK INHIBITOR FOR USE IN THERAPY, IN PARTICULAR MYD88 MUTATED DISEASES<br/>[FR] DÉRIVÉ PYRAZOLOPYRIMIDINE COMME INHIBITEUR HCK POUR L'UTILISATION EN THÉRAPIE, EN PARTICULIER DE MALADIES À MUTATION MYD88
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2021071922A1

  公开（公告）日：2021-04-15

  Provided herein are methods of treating diseases (e.g., proliferative disease (e.g., cancer (e.g., breast cancer, colon cancer, testicular cancer, CNS cancer, stomach cancer, lymphoma (e.g., B-cell lymphoma (e.g., lymphoplasmacytic lymphoma (e.g., IgM secreting lymphoplasmacytic lymphoma (i.e., Waldenstrom's Macroglobulinemia), non-IgM secreting lymphoplasmacytic lymphoma)), diffuse large B-cell lymphoma (e.g., activated B -cell-like (ABC)- DLBCL, germinal center B -cell-like (GBC)-DLBCL), follicular lymphoma, marginal zone B-cell lymphoma, small lymphocytic lymphoma, mantle cell lymphoma), and leukemia (e.g., chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia, myelogenous leukemia (e.g., chronic myelogenous leukemia, acute myelogenous leukemia))))) comprising administering to the subject in need thereof a therapeutically effective amount of Compound (I). Further provided are methods for treating disease resistant to treatment with BTK inhibitors (e.g., ibmtinib). Formula (I)

  本文提供了治疗疾病的方法（例如增殖性疾病（例如癌症（例如乳腺癌、结肠癌、睾丸癌、中枢神经系统癌症、胃癌、淋巴瘤（例如B细胞淋巴瘤（例如淋巴浆细胞淋巴瘤（例如分泌IgM的淋巴浆细胞淋巴瘤（即Waldenstrom的大球蛋白血症），非分泌IgM的淋巴浆细胞淋巴瘤）），弥漫性大B细胞淋巴瘤（例如激活的B细胞样（ABC）-DLBCL，生发中心B细胞样（GBC）-DLBCL），滤泡性淋巴瘤，边缘区B细胞淋巴瘤，小淋巴细胞淋巴瘤，曼托细胞淋巴瘤）和白血病（例如慢性淋巴细胞白血病（CLL），急性淋巴细胞性白血病，髓系白血病（例如慢性髓细胞白血病，急性髓细胞白血病）））），其包括向需要治疗的受试者施用化合物（I）的治疗有效量。此外，还提供了治疗对BTK抑制剂（例如伊布替尼）治疗耐药的疾病的方法。公式（I）。
• [EN] PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS<br/>[FR] PYRAZOLOPYRIMIDINES EN TANT QU'AGENTS THERAPEUTIQUES
  申请人：BASF AG

  公开号：WO2001019829A2

  公开（公告）日：2001-03-22

  The present invention provides compounds of Formula (I), including pharmaceutically acceptable salts and/or prodrugs thereof, where G, Ra, R2, R3 are defined as described herein and their use as protein Kinase inhibitors.

  本发明提供了式（I）的化合物，包括其药学上可接受的盐和/或前药，其中G、Ra、R2、R3的定义如本文所述，并且它们作为蛋白激酶抑制剂的用途。
• Method of treating transplant rejection
  申请人：Waegell Wendy

  公开号：US20050008640A1

  公开（公告）日：2005-01-13

  This invention relates to a method of treating transplant rejection comprising administering to a patient a pharmaceutical composition comprising an lck inhibitor and a calcineurin inhibitor or an immunosuppressant.

  本发明涉及一种治疗移植排斥的方法，包括向患者施用一种药物组合物，该药物组合物包括lck抑制剂和钙调蛋白酶抑制剂或免疫抑制剂。
• AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA
  申请人：RIKEN

  公开号：US20150210698A1

  公开（公告）日：2015-07-30

  This invention relates to an agent for treating or inhibiting recurrence of acute myeloid leukemia and an agent for inhibiting growth of leukemia stem cells comprising a compound represented by formula (I) or a salt thereof: wherein Ar 1 and Ar 2 each represent aryl or heteroaryl; L represents O, S, NH, NHCO, or CONH; X represents CH or N; Y represents C 1-3 -alkylene; Z 1 represents hydrogen, C 1-6 -alkyl, amino-C 1-6 -alkyl, C 1-6 -alkylamino-C 1-6 -alkyl, di(C 1-6 -alkyl)amino-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, or carboxy-C 1-6 -alkyl; and Z 2 represents C 1-6 -alkyl, amino-C 1-6 -alkyl, C 1-6 -alkylamino-C 1-6 -alkyl, di(C 1-6 -alkyl)amino-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkoxy-C 1-6 -alkyl, or carboxy-C 1-6 -alkyl, Z 1 and Z 2 may, together with adjacent nitrogen, form a heterocyclic group containing as a ring member one or more hetero atoms, in addition to the nitrogen adjacent to Z 1 and Z 2 .

  本发明涉及一种用于治疗或抑制急性髓性白血病复发的药物和一种抑制白血病干细胞生长的药物，包括式（I）或其盐所表示的化合物：其中Ar1和Ar2分别表示芳基或杂环芳基；L表示O、S、NH、NHCO或CONH；X表示CH或N；Y表示C1-3-烷基；Z1表示氢、C1-6-烷基、氨基-C1-6-烷基、C1-6-烷基氨基-C1-6-烷基、二（C1-6-烷基）氨基-C1-6-烷基、羟基-C1-6-烷基、C1-6-烷氧基-C1-6-烷基或羧基-C1-6-烷基；Z2表示C1-6-烷基、氨基-C1-6-烷基、C1-6-烷基氨基-C1-6-烷基、二（C1-6-烷基）氨基-C1-6-烷基、羟基-C1-6-烷基、C1-6-烷氧基-C1-6-烷基或羧基-C1-6-烷基，Z1和Z2可以与相邻的氮一起形成含有一个或多个杂原子的杂环基团，除了与Z1和Z2相邻的氮。